Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Eyes and Vision · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 3 · 50%High 0 · 0%

Methotrexate vs mycophenolate

Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU

It is very uncertain whether methotrexate changes proportion of participants with confirmed macular edema (lower… compared with mycophenolate (very low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 0.49 [0.19, 1.3]
1 study · 35 participants
Very low

Methotrexate vs mycophenolate

Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU

Methotrexate probably leads to higher proportion of participants achieving steroid‐sparing control§… compared with mycophenolate (moderate certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 1.23 [1.01, 1.5]
2 studies · 261 participants
Moderate

Methotrexate vs mycophenolate

Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU

Methotrexate showed no clear difference in proportion of participants experiencing complications or requiring… compared with mycophenolate (low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 0.99 [0.43, 2.27]
2 studies · 296 participants
Low

Methotrexate vs mycophenolate

Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU

Methotrexate probably leads to higher proportion of participants achieving control of inflammation§… compared with mycophenolate (moderate certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 1.23 [1.01, 1.5]
2 studies · 261 participants
Moderate

Methotrexate vs mycophenolate

Change in BCVA (lower logMAR indicate better vision) · NIIPPU

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 490 participants
Moderate

Methotrexate vs mycophenolate

Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU

The review found no eligible studies for this question.

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found